Grundinformationen
- Standard-SMILES
CCN(CC)CCNC(=O)c1ccc(N)cc1.Cl- InChIKey
ABTXGJFUQRCPNH-UHFFFAOYSA-N- Summenformel
- C13H22ClN3O
- Durchschnittliche Molmasse
- 271,78 g/mol
- Monoisotopische Masse
- 271,14514
Überblick
Procainamide Hydrochloride is the hydrochloride salt form of procainamide, an amide derivative exhibiting class 1A antiarrhythmic property and analog of procaine. Procainamide hydrochloride reversibly binds to and blocks activated (open) voltage-gated sodium channels, thereby blocks the influx of sodium ions into the cell, which leads to an increase in threshold for excitation and inhibit depolarization during phase 0 of the action potential. In addition, the effective refractory period (ERP), action potential duration (APD), and ERP/APD ratios are increased, resulting in decreased impulse conduction velocity. The lasting action potential may also be due to blockage of outward K+ currents. The result is a decrease in automaticity, increase in refractory period and slowing of impulse conduction.
Namen und Bezeichner
- Bevorzugter Name
- Procainamide Hydrochloride
- IUPAC
- 4-amino-N-[2-(diethylamino)ethyl]benzamide;hydrochloride
Namen und Synonyme
Weitere Namen anzeigen
Datenbank-Bezeichner
- CAS
614-39-1- PubChem CID
- 66068
- DTXSID
DTXSID2049422- ChEMBL
CHEMBL605- UNII
- SI4064O0LX
- EC Number
- 210-381-7
Eigenschaften
Berechnete Struktureigenschaften
- Polarare Oberfläche (TPSA)
- 58,4 Ų
- H-Brücken-Donoren
- 3
- H-Brücken-Akzeptoren
- 3
- Frei drehbare Bindungen
- 6
- Schwere Atome
- 18
- Formalladung
- 0
- Komplexität
- 221
Experimentelle und physikochemische Eigenschaften
Human Drugs
FDA approved drugs -> Active ingredient
FDA approved drugs -> Active ingredient
Sicherheit und Regulatorisches
GHS-Klassifizierung
GHS Classification
Warning
H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]
P261, P264, P264+P265, P270, P271, P280, P301+P317, P302+P352, P304+P340, P305+P351+P338, P319, P321, P330, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 47 reports by companies from 9 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
Gefahrenhinweise
Toxikologische Informationen
Drug Induced Liver Injury
Drug Induced Liver Injury Rank (DILIrank 2.0)
Procainamide hydrochloride
vLess-DILI-concern
4
Adverse reactions
DOI:10.1016/j.drudis.2016.02.015
Chemie und Industrie
Pharmakologische Informationen
FDA Pharmacological Classification
PROCAINAMIDE HCI
Antiarrhythmic [EPC]
PROCAINAMIDE HYDROCHLORIDE
Antiarrhythmic [EPC]
MeSH Pharmacological Classification
Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade.
A class of drugs that inhibit the activation of VOLTAGE-GATED SODIUM CHANNELS.
Verwendung und Herstellung
Zugehörige Reaktionen
Verknüpfte Notizen
Wird geladen…